Despite having great science and a proven ability to get drugs approved, Europe’s biotech ecosystem will remain in the shadows of the US as long as investors continue to adopt a risk-averse culture.
Europe Biotech Sector Superb At Science But Still Scared To Take Risks
Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.
